Study reveals new drug target for rheumatoid arthritis
New research at the Kennedy Institute reveals potential of a novel class of drugs for the treatment of rheumatoid arthritis.
Read moreKey link discovered between tissue cell type and different forms of arthritis
Pioneering research by scientists at the Universities of Oxford and Birmingham published today in Nature brings us a step closer to developing targeted therapies for inflammatory diseases.
Read moreShowcasing a new approach to arthritis research
A recent workshop at Pembroke College, Oxford, provided a showcase for research within the Arthritis Therapy Acceleration Programme (A-TAP) aimed at speeding up the delivery of new drugs for immune-mediated inflammatory disease (IMIDs).
Read moreKennedy Institute of Rheumatology
A world-leading medical research centre where discovery research drives the development of transformative therapies for chronic inflammatory and degenerative disease.
240 Staff, students and academic visitors
30 Nationalities
£70M+ in Research Income
Select Publications
-
cIAP1/2 inhibition synergizes with TNF inhibition in autoimmunity by down-regulating IL-17A and inducing Tregs.
Kawalkowska JZ. et al, (2019), Sci Adv, 5
-
Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease.
Friedrich M. et al, (2019), Immunity, 50, 992 - 1006
-
Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis.
von Loga IS. et al, (2019), Ann Rheum Dis
-
Immuno-phenotypes of Pancreatic Ductal Adenocarcinoma: Meta-analysis of transcriptional subtypes.
de Santiago I. et al, (2019), Int J Cancer